← FDA DRUG APPROVALS

FDA ANDA · ANDA077022

CILOSTAZOL

Sponsor: EPIC PHARMA LLC

APPLICATION
ANDA077022
TYPE
ANDA
ORIGINAL APPROVAL
2004-11-23
LATEST ACTION
2020-11-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CILOSTAZOLPrescription
CILOSTAZOL 100MG · TABLET · ORAL
CILOSTAZOLPrescription
CILOSTAZOL 50MG · TABLET · ORAL

Approval history

2020-11-18Labeling · Supplement 9 · standardAP
2017-03-21Labeling · Supplement 8 · standardAP
2010-07-06Labeling · Supplement 7AP
2010-05-27Labeling · Supplement 5AP
2008-02-14Labeling · Supplement 3AP
2006-02-14Labeling · Supplement 2AP
2004-11-23OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →